← Every applicant
Lannett Co Inc FDA Approvals
8 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| FAMOTIDINENew drugJun 2, 2025FOR SUSPENSION, ORAL |
| PRAZOSIN HYDROCHLORIDENew drugJan 3, 2024CAPSULE, ORAL |
| LISDEXAMFETAMINE DIMESYLATENew drugAug 25, 2023CAPSULE, ORAL |
| SOLIFENACIN SUCCINATENew drugJun 6, 2023TABLET, ORAL |
| DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATENew drugJul 8, 2022TABLET, ORAL |
| DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATENew drugNov 26, 2021CAPSULE, EXTENDED RELEASE, ORAL |
| METHADONE HYDROCHLORIDENew drugMar 3, 2021CONCENTRATE, ORAL |
| CHLORPROMAZINE HYDROCHLORIDENew drugJan 22, 2021TABLET, ORAL |